From mind to mouth - Olaparib
Clever research concepts finally bring new player to companion diagnostics market
The recent admission of Olaparib treatment by FDA and EMA caused quite a stir in cancer therapeutics and for good reasons: Patients of ovarial carcinoma and related carcinomas now have a perspective of personalized and improved treatment while at the same time the authorities’ decision underlines the growing acceptance of companion diagnostics (CDx) based therapies. With this April newsletter we invite you to take a look at how ideas emerging from biomarker research can successfully result in CDx market access and how IMGM’s services can support you on this way.
Find more details in the PDF.